Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer

Sumiyuki Nishida, Shigeo Koido, Yutaka Takeda, Sadamu Homma, Hideo Komita, Akitaka Takahara, Satoshi Morita, Toshinori Ito, Soyoko Morimoto, Kazuma Hara, Akihiro Tsuboi, Yoshihiro Oka, Satoru Yanagisawa, Yoichi Toyama, Masahiro Ikegami, Toru Kitagawa, Hidetoshi Eguchi, Hiroshi Wada, Hiroaki Nagano, Jun NakataYoshiki Nakae, Naoki Hosen, Yusuke Oji, Toshio Tanaka, Ichiro Kawase, Atsushi Kumanogoh, Junichi Sakamoto, Yuichiro Doki, Masaki Mori, Toshifumi Ohkusa, Hisao Tajiri, Haruo Sugiyama

研究成果: Contribution to journalArticle査読

63 被引用数 (Scopus)

抄録

Wilms tumor gene (WT1) protein is an attractive target for cancer immunotherapy. We aimed to investigate the feasibility of a combination therapy consisting of gemcitabine and WT1 peptide-based vaccine for patients with advanced pancreatic cancer and to make initial assessments of its clinical efficacy and immunologic response. Thirty-two HLA-A*24:02 patients with advanced pancreatic cancer were enrolled. Patients received HLA-A*24:02- restricted, modified 9-mer WT1 peptide (3 mg/body) emulsified with Montanide ISA51 adjuvant (WT1 vaccine) intradermally biweekly and gemcitabine (1000 mg/m) on days 1, 8, and 15 of a 28-day cycle. This combination therapy was well tolerated. The frequencies of grade 3-4 adverse events for this combination therapy were similar to those for gemcitabine alone. Objective response rate was 20.0% (6/30 evaluable patients). Median survival time and 1-year survival rate were 8.1 months and 29%, respectively. The association between longer survival and positive delayed-type hypersensitivity to WT1 peptide was statistically significant, and longer survivors featured a higher frequency of memory-phenotype WT1-specific cytotoxic T lymphocytes both before and after treatment. WT1 vaccine in combination with gemcitabine was well tolerated for patients with advanced pancreatic cancer. Delayed-type hypersensitivity- positivity to WT1 peptide and a higher frequency of memory-phenotype WT1-specific cytotoxic T lymphocytes could be useful prognostic markers for survival in the combination therapy with gemcitabine and WT1 vaccine. Further clinical investigation is warranted to determine the effectiveness of this combination therapy.

本文言語英語
ページ(範囲)105-114
ページ数10
ジャーナルJournal of Immunotherapy
37
2
DOI
出版ステータス出版済み - 2 2014

All Science Journal Classification (ASJC) codes

  • 免疫アレルギー学
  • 免疫学
  • 薬理学
  • 癌研究

フィンガープリント

「Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル